Wise, Robert
Calverley, Peter MA
Dahl, Ronald
Dusser, Daniel
Metzdorf, Norbert
Müller, Achim
Fowler, Andy
Anzueto, Antonio
Article History
Received: 2 April 2015
Revised: 14 August 2015
Accepted: 15 September 2015
First Online: 5 November 2015
Competing interests
: RW reports receiving consulting fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Mylan, Novartis, Pfizer, Pulmonx, Roche, Spiration and Sunovion, with grant support from Boehringer Ingelheim, Forest Laboratories, GlaxoSmithKline, Takeda and Pearl Therapeutics; PMAC reports receiving consulting fees, lecture fees and travel support from Boehringer Ingelheim, GlaxoSmithKline, Novartis and Takeda; RD reports receiving consulting fees, lecture fees and grant support from Boehringer Ingelheim and Novartis; DD reports receiving consulting fees, lecture fees and payment for the development of educational activities from Boehringer Ingelheim, Chiesi, Dey Pharma, Novartis, Nycomed and Pfizer; AA reports receiving consulting fees, lecture fees and travel support from AstraZeneca, Boehringer Ingelheim, Forest Laboratories, GlaxoSmithKline and Novartis, and grant support to the University of Texas Health Science Centre from GlaxoSmithKline; NM, AF and AM are employees of Boehringer Ingelheim.